Advertisement Florida Biologix to formulate, fill NanoSonic Trappsol Cyclo - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Florida Biologix to formulate, fill NanoSonic Trappsol Cyclo

NanoSonic Products and Florida Biologix have signed a contract for the formulation and filling of the sterile liquid form of Trappsol Cyclo product.

NanoSonic’s Trappsol Cyclo is FDA and EMEA designated orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer’s.

Trappsol Cyclo is currently being administered in the US under a compassionate use IND.

Florida Biologix will formulate, fill, label, test and package 3,000 vials of this therapy for patients with this devastating disease.

Childhood Alzheimer’s affects children and adults and manifests with progressive neurological symptoms.